Following is a abstract of present well being information briefs.

Musk expects mind chip start-up Neuralink to implant ‘first case’ this yr

Billionaire entrepreneur Elon Musk expects his brain-chip startup Neuralink to start out its first human trial this yr, he mentioned on Friday in France. Speaking on the VivaTech occasion in Paris, co-founder Musk mentioned Neuralink plans to implant a tetraplegic or paraplegic affected person throughout a webcast monitored by Reuters. While Musk did not specify what number of sufferers his firm would implant or for a way lengthy, “it’s looking like the first case will be later this year,” mentioned Musk, who can be CEO of electrical carmaker Tesla, social media platform Twitter and the SpaceX rocket launch firm.

Humana joins UnitedHealth in flagging value hit from rising surgical procedures

Humana Inc on Friday joined bigger well being insurer UnitedHealth in warning of a soar in medical prices this yr as a consequence of higher-than-expected demand for surgical procedures and different medical procedures. Pandemic-driven restrictions and hospital staffing shortages had led to lengthy delays in elective procedures similar to hip and knee replacements, particularly amongst older adults at greater danger of contracting extreme COVID-19.

Meta rolls again measures to deal with COVID misinformation

Meta Platforms mentioned on Friday a coverage that was put in place to curb the unfold of misinformation associated to COVID-19 on Facebook and Instagram would not be in impact globally.

Social media platforms similar to Facebook and Twitter got here below immense stress to deal with misinformation associated to the pandemic, together with false claims about vaccines, prompting them to take stringent measures.

Roche’s most cancers remedy will get US FDA nod, heating up competitors with AbbVie

The U.S. Food and Drug Administration (FDA) greenlighted Roche Holding AG’s experimental remedy to deal with a kind of superior blood most cancers, practically a month after the approval of a rival remedy from AbbVie Inc. Roche’s Columvi, an antibody-based remedy chemically often known as glofitamab, was permitted to deal with diffuse massive B-cell lymphoma in adults, who had acquired a minimum of two prior strains of remedy earlier than their most cancers relapsed, the Swiss drugmaker mentioned late on Thursday.

For teams preventing U.S. opioid disaster, settlement cash may be laborious to come back by

Companies accused of fueling the U.S. opioid disaster have to this point paid out greater than $3 billion to compensate states, however has any of the cash reached the individuals who want it? It relies upon the place you reside. Yes, if you happen to’re in Massachusetts; no, in Texas. A collection of landmark settlements since 2021 with high drug distributors, pharmacies and drugmakers together with Johnson & Johnson set compensation at a complete of greater than $50 billion nationwide.

EU ‘deeply involved’ by dangers of recent psychoactive medicine – report

A surge in manufacturing of potent new medicine in Europe that may result in poisoning and dying requires extra funding in providers and stronger insurance policies in opposition to illicit substances, an EU examine mentioned on Friday. The report by the Lisbon-based EU medicine company (EMCDDA) mentioned the dimensions and complexity of illicit drug output inside Europe was rising and that customers have been now uncovered to a wider vary of psychoactive substances.

Exclusive-WHO says poisonous syrup danger ‘ongoing’, extra nations hit

There is an ongoing international risk posed by poisonous cough syrups, the World Health Organization (WHO) informed Reuters, saying it was now working with six extra nations than beforehand revealed to trace the doubtless lethal youngsters’s medicines. The U.N. company has already named 9 nations the place tainted syrups could have been on sale, after the deaths of greater than 300 infants on three continents final yr have been linked to the medicine.

US FDA advises COVID vaccine makers to develop pictures aimed toward XBB.1.5 variant

The U.S. Food and Drug Administration (FDA) mentioned on Friday it has suggested producers which can be updating their COVID-19 vaccines to develop monovalent pictures to focus on the XBB.1.5 subvariant. So-called monovalent, or single-target vaccines, could be a change from the newest bivalent COVID boosters that focused each the unique and Omicron strains of the coronavirus.

Eli Lilly’s migraine drug fails to show superiority to Pfizer’s

Eli Lilly mentioned on Friday its migraine prevention drug failed to indicate superiority to a rival from Pfizer Inc in a post-approval examine. The three-month examine, which concerned 580 sufferers, was the first-of-its-kind to check the 2 permitted medicine – Emgality and Nurtec, a drug Pfizer gained final yr by way of an $11.6 billion acquisition of Biohaven Pharmaceutical.

Bristol Myers sues US authorities over Medicare drug worth negotiation plan

Bristol Myers Squibb Co on Friday sued the U.S. authorities in an try and halt the Medicare drug worth negotiation program that analysts consider will contain one in every of its top-selling medicines, saying it violates the Fifth and First Amendments to the U.S. Constitution. This is the third lawsuit to this point difficult the legislation – a part of President Joe Biden’s signature Inflation Reduction Act (IRA) – which the pharmaceutical business says will curtail earnings and compel them to drag again on growing groundbreaking new therapies.

(This story has not been edited by Devdiscourse employees and is auto-generated from a syndicated feed.)